Spots Global Cancer Trial Database for Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
Official Title: A Clinical Study of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Patients With Advanced Non-small Cell Lung Cancer
Study ID: NCT03525782
Study Description
Brief Summary: The study is to assess the safety and efficacy of the anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells for patients with advanced non-small cell lung cancer.
Detailed Description: This is a combined phase 1 and 2 clinical study. The study is to assess the safety and efficacy of the anti-MUC1 CAR T cells and /or PD-1 knockout engineered T cells for patients with advanced non-small cell lung cancer. The treatment outcomes will be compared.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China
Professor Size Chen, Guangzhou, Guangdong, China
Professor Size Chen, Guangzhou, Guangdong, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
